ORTHOCELL LIMITED ORDINARY (OCC) Short Interest
ORTHOCELL LIMITED ORDINARY (ASX:OCC) had 0.38% of shares reported as short positions as of 16 July 2026, representing 1,037,550 shares. ORTHOCELL LIMITED ORDINARY operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Orthocell
Orthocell is a leader in the regenerative medicine sector, focusing on innovative treatments for chronic degenerative diseases and injuries. The company specializes in developing collagen medical devices and cell therapies that leverage the body's natural repair mechanisms. Orthocell's products are designed to enhance surgical repair and promote tissue regeneration, positioning it as a pioneer in the biotechnology and life sciences industry.
Short position
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4OCC intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Orthocell
Latest OCC news
All news- Q4 FY26 ASX Investor Presentation
asx
- Orthocell Shares Rise: What Could Drive the Regenerative-Medicine Stock's Next Move? - Kalkine
googlenews
- Orthocell (ASX:OCC) Expands Global Reach With Strong Revenue Momentum
kalkine
- Record revenue for Orthocell as Remplir rollout gathers pace in US
stockhead
- Quarterly Activity Report & Appendix 4C
asx
About
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss OCC
Start a research thread or post the first pulse update